J. F. Chatal, F. Kraber-bodere, C. Bodet-milin, and C. Rousseau, Which cytotoxic payload: chemotherapeutic (ADC) or radionuclide (ARC) ? Curr Cancer Therapy Rev, vol.12, p.54, 2016.

J. A. Siegel, D. A. Pawlyk, R. E. Lee, N. L. Sasso, J. A. Horowitz et al., Tumor, red marrow, and organ dosimetry for 131I-labeled anti-carcinoembryonic antigen monoclonal antibody, Cancer Res, vol.50, pp.1039-1081, 1990.

M. Bardiès, S. Bardet, A. Faivre-chauvet, P. Peltier, J. Y. Douillard et al., Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer, J Nucl Med, vol.37, pp.1853-1862, 1996.

P. Zanzonico, Radioimmunotherapy of micrometastases: a continuing evolution, J Nucl Med, vol.33, pp.2180-2183, 1992.

G. L. Denardo, J. Schlom, D. J. Buchsbaum, R. F. Meredith, J. A. O'donoghue et al., Rationales, evidence, and design considerations for fractionated radioimmunotherapy, Cancer, vol.94, pp.1332-1380, 2002.

J. Schlom, A. Molinolo, J. F. Simpson, K. Siler, M. Roselli et al., Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy, J Natl Cancer Inst, vol.82, pp.763-71, 1990.

T. M. Illidge, S. Mayes, R. Pettengell, A. T. Bates, M. Bayne et al., , vol.90

, Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria, J Clin Oncol, vol.32, pp.212-220, 2014.

C. W. Scholz, A. Pinto, W. Linkesch, O. Lindén, A. Viardot et al., Yttriumibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial, J Clin Oncol, vol.90, pp.308-321, 2013.

J. S. Batra, B. S. Karir, S. Vallabhajosula, P. J. Christos, G. Hodes et al., Fractionated dose radiolabeled antiprostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) with or without docetaxel for metastatic castration-resistant prostate cancer (mCRPC), ASCO Meeting Abstr, vol.33, p.194, 2015.

S. T. Tagawa, M. I. Milowsky, M. Morris, S. Vallabhajosula, C. P. Akhtar et al., Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer, Clin Cancer Res, vol.19, pp.5182-91, 2013.

J. Tschmelitsch, E. Barendswaard, C. Williams, T. J. Yao, A. M. Cohen et al., Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil), Cancer Res, vol.57, pp.2181-2187, 1997.

J. Wong, D. Z. Chu, D. M. Yamauchi, L. E. Williams, A. Liu et al., A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies, Clin Cancer Res, vol.6, pp.3855-63, 2000.

J. Wong, S. Shibata, L. E. Williams, C. S. Kwok, A. Liu et al., A phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer, Clin Cancer Res, vol.9, pp.5842-52, 2003.

S. A. Gulec, S. J. Cohen, K. L. Pennington, L. S. Zuckier, R. J. Hauke et al., Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial, Clin Cancer Res, vol.17, pp.4091-100, 2011.

A. J. Ocean, K. L. Pennington, M. J. Guarino, A. Sheikh, T. Bekaii-saab et al., Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: a phase 1 trial, Cancer, vol.118, pp.5497-506, 2012.

N. H. Bander, M. I. Milowsky, D. M. Nanus, L. Kostakoglu, S. Vallabhajosula et al., Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer, J Clin Oncol, vol.23, pp.4591-601, 2005.

S. T. Tagawa, Y. E. Whang, G. Kaur, S. Vallabhajosula, P. J. Christos et al., Phase I trial of docetaxel/prednisone plus fractionated dose radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody 177lu-J591 in patients with metastatic, castrationresistant prostate cancer (mCRPC), ASCO Meeting Abstr, vol.32, p.5064, 2014.

J. Barbet, P. Peltier, S. Bardet, J. P. Vuillez, I. Bachelot et al., Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPAindium bispecific antibody, J Nucl Med, vol.39, pp.1172-1180, 1998.

F. Kraeber-bodéré, C. Rousseau, C. Bodet-milin, C. Mathieu, F. Guérard et al., Tumor immunotargeting using innovative radionuclides, Int J Mol Sci, vol.16, pp.3932-54, 2015.

P. Salaun, L. Campion, C. Bournaud, A. Faivre-chauvet, J. Vuillez et al., Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement, J Nucl Med, vol.53, pp.1185-92, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00932253

E. A. Rossi, D. M. Goldenberg, T. M. Cardillo, W. J. Mcbride, R. M. Sharkey et al., Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting, Proc Natl Acad Sci, vol.103, pp.6841-6847, 2006.

R. M. Sharkey, W. J. Mcbride, H. Karacay, K. Chang, G. L. Griffiths et al., A universal pretargeting system for cancer detection and therapy using bispecific antibody, Cancer Res, vol.63, pp.354-63, 2003.

R. Schoffelen, W. Van-der-graaf, G. Franssen, R. M. Sharkey, D. M. Goldenberg et al., Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice, J Nucl Med, vol.51, pp.1780-1787, 2010.

R. Schoffelen, W. Woliner-van-der-weg, E. P. Visser, D. M. Goldenberg, R. M. Sharkey et al., Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer, Eur J Nucl Med Mol Imaging, vol.41, pp.1593-602, 2014.

C. Bodet-milin, L. Ferrer, A. Rauscher, D. Masson, L. Rbah-vidal et al., Pharmacokinetics and dosimetry studies for optimization of Pretargeted Radioimmunotherapy in CEA-expressing advanced lung Cancer patients, Front Med (Lausanne), vol.2, p.84, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01258870

J. Chatal, F. Davodeau, M. Cherel, and J. Barbet, Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors, J Cancer Res Ther, vol.5, issue.1, pp.36-40, 2009.

F. Guérard, J. Gestin, and M. W. Brechbiel, Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted ?-particle therapy, Cancer Biother Radiopharm, vol.28, pp.1-20, 2013.

J. G. Jurcic, S. M. Larson, G. Sgouros, M. R. Mcdevitt, R. D. Finn et al., Targeted alpha particle immunotherapy for myeloid leukemia, Blood, vol.100, pp.1233-1242, 2002.

J. G. Jurcic and T. L. Rosenblat, Targeted alpha-particle immunotherapy for acute myeloid leukemia, Am Soc Clin Oncol Educ Book, pp.126-157, 2014.

R. Meredith, J. Torgue, S. Shen, D. R. Fisher, E. Banaga et al., Dose escalation and dosimetry of first-in-human ? radioimmunotherapy with 212Pb-TCMC-trastuzumab, J Nucl Med, vol.55, pp.1636-1678, 2014.

J. J. Orozco, T. Bäck, A. Kenoyer, E. R. Balkin, D. K. Hamlin et al., Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model, Blood, vol.121, pp.3759-67, 2013.

M. R. Zalutsky, D. A. Reardon, G. Akabani, R. E. Coleman, A. H. Friedman et al., Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6, J Nucl Med, vol.49, pp.30-38, 2008.

H. Andersson, E. Cederkrantz, T. Bäck, C. Divgi, J. Elgqvist et al., Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2 -a phase I study, J Nucl Med, vol.50, pp.1153-60, 2009.

F. Kraeber-bodéré, C. Bodet-milin, C. Rousseau, T. Eugène, A. Pallardy et al., Radioimmunoconjugates for the treatment of cancer, Semin Oncol, vol.41, pp.613-635, 2014.

C. Rousseau, A. L. Ruellan, K. Bernardeau, F. Kraeber-bodéré, S. Gouard et al., Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors, EJNMMI Res, vol.1, issue.20, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00626326

I. H. Song, T. S. Lee, Y. S. Park, J. S. Lee, B. C. Lee et al., Immuno-PET imaging and radioimmunotherapy of 64Cu-/177Lu-labeled anti-EGFR antibody in esophageal squamous cell carcinoma model, J Nucl Med, vol.57, p.1105, 2016.

S. Rizvi, O. J. Visser, M. Vosjan, A. Van-lingen, O. S. Hoekstra et al., Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET, Eur J Nucl Med Mol Imaging, vol.39, pp.512-532, 2012.

L. R. Perk, O. J. Visser, M. Stigter-van-walsum, M. Vosjan, G. Visser et al., Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography, Eur J Nucl Med Mol Imaging, vol.33, pp.1337-1382, 2006.